Galata Acquisition Corp. II

# Signal Note: Driehaus Capital / Galata Acquisition Corp II Driehaus' $2.0M entry into blank-check vehicle LATAW suggests conviction in an unnamed biotech target—likely a clinical-stage company given Galata's typical focus on pre-revenue assets. Without disclosed merger terms, the catalyst hinges on deal announcement and subsequent clinical/regulatory milestones, though the position size is modest relative to Driehaus' $30B+ AUM and implies either early conviction or a portfolio satellite position rather than core conviction.